###### Key messages

What is the key question?
=========================

-   Do statins have an effect on disease-related outcomes in patients with idiopathic pulmonary fibrosis (IPF)?

What is the bottom line?
========================

-   In a large and well defined cohort of patients with IPF, statins were associated with reductions in IPF-related mortality, hospitalisation and disease progression compared with patients who did not receive statins.

Why read on?
============

-   Statins are frequently prescribed for concomitant cardiovascular disease and risk factors in patients with IPF, and have previously been linked with both detrimental and beneficial actions on IPF progression.

Introduction {#s1}
============

Idiopathic pulmonary fibrosis (IPF) is a serious, debilitating and progressive lung disease that presents with exertional dyspnoea and cough.[@R1] IPF is diagnosed more frequently among men than women, during the seventh or eighth decade of life and among current or ex-smokers.[@R4] IPF is associated with substantial healthcare requirements and patients with IPF typically require frequent hospitalisations as a consequence of their disease.[@R5] Furthermore, the prognosis for patients with IPF is poor and survival rates are lower than those reported for many common cancers.[@R6] [@R7] The 5-year survival rate for patients from the time of diagnosis is between 20% and 40%,[@R8] with a median survival of between 2 years and 5 years.[@R2] [@R7]

Two antifibrotic drugs are approved for the treatment of IPF, pirfenidone[@R9] [@R10] and nintedanib.[@R11] Both drugs have been shown to significantly reduce the decline in FVC compared with placebo among patients with IPF.[@R9] Pirfenidone has also been shown to improve survival among patients with IPF: a pooled analysis of data found a 48% reduction in mortality compared with placebo after 1 year of treatment with pirfenidone (p=0.01).[@R9]

Cardiovascular (CV) comorbidities are common in IPF[@R12] and medications are often required to treat patients with CV risk factors. This includes the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor or 'statin' class of drugs, which are widely used for their cholesterol-lowering effects and associated reduction in the risk for CV morbidity.[@R13] [@R14] The potential for additional benefits from statin therapy has been investigated previously. For example, statins have been shown to attenuate the decline in pulmonary function associated with normal ageing, with the magnitude of the protective effect apparently modified by smoking status.[@R15] Furthermore, the effect of statins on disease-related outcomes in patients with COPD has also been investigated.[@R16] However, the relationship between statins and the development of interstitial lung disease (ILD) is controversial. Case reports and, most recently, a regression analysis of current and former smokers included in the COPDGene study suggest that statin use may be associated with the presence of interstitial lung abnormalities, at least among patients who are current or ex-smokers.[@R17] [@R18]

In contrast, a recent analysis of a health administrative database that included 6665 individuals with possible or probable ILD and 26 660 matched control subjects, did not reveal an association between statin use and the incidence of ILD.[@R19] Conflicting data have also emerged with regard to the effect of statins in patients with established lung disease such as IPF. Animal studies have shown that statins prevent the development of pulmonary fibrosis, although they do not appear to attenuate established pulmonary fibrosis.[@R20] In a small retrospective analysis of data from 35 patients with IPF, no association between statin therapy and mortality was identified.[@R21] However, a more recent analysis of data from the national Danish Patients Registry found that statin use was associated with reduced mortality among patients with ILD, including those with IPF.[@R22]

To further investigate the potential effects of statins in patients with IPF, a post hoc analysis was performed using data from the placebo arms of the pirfenidone phase III programme. The effect of statins on mortality and other clinically relevant disease-related outcomes was investigated in this well defined population of patients with IPF.

Materials and methods {#s2}
=====================

This was a post hoc analysis of data from the placebo arms of three phase III, randomised, controlled, double-blind clinical trials of pirfenidone in IPF: Study 016, Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND; NCT01366209);[@R9] and Study 004 and Study 006, Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis (CAPACITY; NCT00287729 and NCT00287716, respectively).[@R10] Patient enrolment took place from July 2011 to January 2013, and from April 2006 to November 2008 in the ASCEND and CAPACITY trials, respectively. ASCEND and CAPACITY were conducted in accordance with the International Conference on Harmonisation Guidelines and the Declaration of Helsinki, as well as the relevant local legal and regulatory requirements of the countries in which the trials were conducted. Written informed consent was obtained from all patients prior to any study procedure.

Patients {#s2a}
--------

ASCEND and CAPACITY recruited patients aged between 40 years and 80 years who had a confirmed diagnosis of IPF by high-resolution CT (HRCT) alone or HRCT plus surgical lung biopsy. Eligible patients had an FVC ≥50% (and ≤90% in the ASCEND trial), per cent predicted carbon monoxide diffusing capacity ≥35% (≥30% and ≤90% in the ASCEND trial) and a 6-minute walk distance (6MWD) ≥150 m with no evidence of improvement in measures of IPF disease severity over the preceding year. Patients showing significant clinical worsening of IPF as judged by the investigator, or a difference in FVC \>10% between screening and day 1, were excluded. Other exclusion criteria were clinically significant concomitant disease including a history of unstable or deteriorating cardiac disease within the previous 6 months, and active infection or malignancy. Patients with a history of COPD were excluded from ASCEND, but were eligible for the CAPACITY studies if the condition had not led to hospitalisation within 6 months prior to study entry.[@R9] [@R10] The use of concomitant medication, including statins, was ascertained through open-ended questioning by study investigators.

Assessments {#s2b}
-----------

The outcomes evaluated were disease progression (defined as the first occurrence of any of the following: ≥10% absolute decline in per cent predicted FVC, a decline of at least 50 m in 6MWD (both required confirmation at two consecutive assessments at least 6 weeks apart) or death), all-cause mortality, IPF-related mortality (the cause of death was assessed by blinded clinical investigators in CAPACITY and a mortality assessment committee in ASCEND), change from baseline in FVC, change from baseline in 6MWD, all-cause hospitalisation and respiratory-related hospitalisation (defined as a hospitalisation in which the primary reason for admission was determined to be respiratory related by the investigator). The composite outcomes of all-cause mortality or a ≥10% absolute decline in per cent predicted FVC and all-cause mortality or a ≥50 m decline in 6MWD were prespecified outcomes in ASCEND.[@R9] All outcomes were evaluated over 1 year.

![Adjusted 1-year risk of disease progression\*: statin users versus non-users. \*≥10% decrease in % predicted FVC, ≥50 m decline in 6MWD or death. 6MWD, 6-minute walk distance.](thoraxjnl-2016-208819f01){#THORAXJNL2016208819F1}

![Adjusted 1-year risk of ≥10% absolute FVC decline or death: statin users versus non-users.](thoraxjnl-2016-208819f02){#THORAXJNL2016208819F2}

Statistical analysis {#s2c}
--------------------

Demographic and clinical characteristics of the study population categorised by statin use at baseline, and corresponding crude (unadjusted) risks of binary study outcomes among statin users and non-users, were compared. Statistical comparisons were undertaken using an independent-samples t-test for continuous variables and a χ^2^ test for categorical variables.

A shared frailty model (an extension of the Cox proportional hazards model that adjusts for intracluster (ie, intratrial) correlation) was employed to examine the relationship between statin use and study outcomes without adjustment (bivariate model), and with adjustment for age, sex, smoking status, lung function, exercise tolerance, dyspnoea, medical history and CV risk factors (multivariate model). Survival analyses were based on the Kaplan-Meier estimator, and comparisons of statin users and non-users were based on the log-rank test. Only observed data were employed in analyses (ie, missing values were not imputed). Individuals were censored at the time of loss to follow-up, at the time of lung transplantation or at the end of the 1-year follow-up period, whichever occurred first. The presence of multicollinearity, hazards assumptions and treatment of death as a competing risk (where appropriate) were evaluated using published methods.[@R23] [@R24] SAS V.9.3 for Windows was used to evaluate the proportionality assumption for statin use using a time-dependent covariate (ie, interaction between statin and time). Models not considering death as an outcome were estimated, alternatively treating death as a competing risk rather than censoring on death.

Results {#s3}
=======

Patients {#s3a}
--------

A total of 624 patients were included in this post hoc analysis (ASCEND, n=277; CAPACITY, n=347), of whom 276 (44.2%) were receiving statin therapy at baseline (simvastatin, 38.4%; atorvastatin, 34.8%; pravastatin, 9.8%; rosuvastatin, 9.4%; other, 7.6%). The mean (SD) duration of follow-up was 348.3 (58.8) days in patients who received statins and 342.7 (67.8) days in those who did not. During the 1-year follow-up, one statin user and four statin non-users received a lung transplant.

Statin users were older than non-users and a greater proportion of statin users were male ([table 1](#THORAXJNL2016208819TB1){ref-type="table"}).

###### 

Summary of baseline demographics: baseline statin users and non-users

  Parameter                            Statin users (N=276)   Statin non-users (N=348)   p Value
  ------------------------------------ ---------------------- -------------------------- ----------
  Mean age, years (SD)                 68.2 (7.0)             66.3 (7.8)                 0.0014
  Sex, n (%)                                                                             
   Male                                225 (81.5)             240 (69.0)                 0.0004
  Mean % predicted FVC (SD)            72.5 (14.0)            71.6 (13.3)                0.4297
  Mean % predicted DLco\* (SD)         45.4 (10.3)            45.7 (11.7)                0.7329
  Mean 6MWD\*, m (SD)                  407.4 (89.8)           415.3 (97.6)               0.3028
  Mean UCSD-SOBQ score\* (SD)          34.3 (22.1)            35.4 (21.2)                0.5325
  Medical history, n (%)                                                                 
   Cardiovascular disease              127 (46.0)             53 (15.2)                  \<0.0001
   Chronic renal failure               13 (4.7)               7 (2.0)                    0.0573
   COPD                                14 (5.1)               8 (2.3)                    0.0621
  Cardiovascular risk factors, n (%)                                                     
   Hypercholesterolaemia               234 (84.8)             61 (17.5)                  \<0.0001
   Smoker (current/former)             186 (67.4)             198 (56.9)                 0.0074
   Hypertension                        183 (66.3)             157 (45.1)                 \<0.0001
   Obesity†                            125 (45.3)             140 (40.2)                 0.2041
   Diabetes                            75 (27.2)              59 (17.0)                  0.0020

\*Statin users with missing values: DLco, n=1; 6MWD, n=4; UCSD-SOBQ, n=4. Statin non-users with missing values: DLco, n=1; 6MWD, n=5; UCSD-SOBQ, n=3.

†Defined as a body mass index \>30 kg/m^2^.

6MWD, 6-minute walk distance; DLco, carbon monoxide diffusing capacity; UCSD-SOBQ, The University of California in San Diego Shortness of Breath Questionnaire.

Baseline lung function and exercise capacity were similar between the two groups. However, those receiving statins had a significantly higher prevalence of CV disease at baseline. The prevalence of the following CV risk factors was higher among statin users than non-users: hypertension, smoking (current and former), diabetes and hypercholesterolaemia ([table 1](#THORAXJNL2016208819TB1){ref-type="table"}).

Disease-related outcomes {#s3b}
------------------------

Results from the crude analysis and bivariate frailty model are presented in [table 2](#THORAXJNL2016208819TB2){ref-type="table"}.

###### 

Unadjusted 1-year risks of study outcomes for baseline statin users and non-users\*†

  Outcome                                        Crude analysis, n (%)   Bivariate frailty model (statin users vs non-users)                                  
  ---------------------------------------------- ----------------------- ----------------------------------------------------- -------- ------ -------------- --------
  Disease-progression composite outcome‡         103 (37.3)              152 (43.7)                                            0.0737   0.79   0.61 to 1.02   0.0686
   First disease-progression outcome to occur§                                                                                                                
    All-cause mortality                          13 (4.7)                19 (5.5)                                                                             
    Absolute FVC decrease ≥10%                   32 (11.6)               52 (14.9)                                                                            
    6MWD decrease ≥50 m                          62 (22.5)               92 (26.4)                                                                            
  Mortality                                                                                                                                                   
   All-cause                                     18 (6.5)                24 (6.9)                                              0.8528   0.91   0.49 to 1.68   0.7557
   IPF-related                                   15 (5.4)                23 (6.6)                                              0.5423   0.71   0.33 to 1.54   0.3814
  FVC change                                                                                                                                                  
   Absolute decrease ≥10%                        43 (15.6)               70 (20.1)                                             0.1440   0.67   0.46 to 0.99   0.0417
   Relative decrease ≥10%                        77 (27.9)               108 (31.0)                                            0.3943   0.77   0.57 to 1.03   0.0814
   Absolute decrease ≥5%                         109 (39.5)              147 (42.2)                                            0.4881   0.81   0.63 to 1.04   0.0958
   Relative decrease ≥5%                         134 (48.6)              191 (54.9)                                            0.1157   0.76   0.61 to 0.95   0.0174
  Death or absolute FVC decrease ≥10%            57 (9.1)                90 (14.4)                                             0.1277   0.71   0.51 to 0.99   0.0437
  Death or 6MWD decrease ≥50 m                   99 (15.9)               142 (22.8)                                            0.2086   0.85   0.66 to 1.10   0.2157
  6MWD decrease ≥50 m                            69 (25.0)               97 (27.9)                                             0.4918   0.85   0.62 to 1.16   0.3046
  Hospitalisation                                                                                                                                             
   All-cause                                     47 (17.0)               72 (20.7)                                             0.2477   0.78   0.54 to 1.13   0.1818
   Respiratory-related¶                          30 (10.9)               59 (17.0)                                             0.0309   0.64   0.41 to 1.00   0.0496

\*Only confirmed cases included, defined as those for whom follow-up assessment was repeated ≥6 weeks following initial assessment and criteria for outcome were met.

†Patients with missing baseline data were excluded from relevant analyses.

‡Only first event considered in analyses.

§Number of patients who experienced each outcome as their first disease-progression event.

¶Hospitalisation in which the primary reason for admission was determined to be respiratory-related by a blinded clinical investigator.

6MWD, 6-minute walk distance; IPF, idiopathic pulmonary fibrosis.

In multivariate analyses, there was a non-significant treatment effect favouring statin use for the composite disease-progression outcome (multivariate HR 0.75; 95% CI 0.52 to 1.07, p=0.1135) ([figure 1](#THORAXJNL2016208819F1){ref-type="fig"}; [table 3](#THORAXJNL2016208819TB3){ref-type="table"}). Statin users had a significantly lower risk versus non-users for the composite outcome of all-cause mortality or a decrease of ≥50 m in 6MWD (multivariate HR 0.69; 95% CI 0.48 to 0.99, p=0.0465), all-cause hospitalisation (multivariate HR 0.58; 95% CI 0.35 to 0.94, p=0.0289), respiratory-related hospitalisation (multivariate HR 0.44; 95% CI 0.25 to 0.80, p=0.0063) and IPF-related mortality (multivariate HR 0.36; 95% CI 0.14 to 0.95, p=0.0393) ([table 3](#THORAXJNL2016208819TB3){ref-type="table"}). There was no significant difference between treatment groups for ≥10% absolute decline in per cent predicted FVC (multivariate HR 0.81; 95% CI 0.47 to 1.40, p=0.4533), the composite outcome of all-cause mortality or a ≥10% decline in per cent predicted FVC (multivariate HR 0.71; 95% CI 0.48 to 1.07, p=0.1032) ([figure 2](#THORAXJNL2016208819F2){ref-type="fig"}) and all-cause mortality (multivariate HR 0.54; 95% CI 0.24 to 1.21, p=0.1369) ([table 3](#THORAXJNL2016208819TB3){ref-type="table"}).

###### 

Multivariate analyses: baseline statin users versus non-users\*

  Outcome                               Multivariate analyses (statin users vs non-users)                  
  ------------------------------------- --------------------------------------------------- -------------- --------
  Disease progression†                  0.75                                                0.52 to 1.07   0.1135
  Mortality                                                                                                
   All-cause                            0.54                                                0.24 to 1.21   0.1369
   IPF-related                          0.36                                                0.14 to 0.95   0.0393
  FVC                                                                                                      
   Absolute decrease ≥10%               0.81                                                0.47 to 1.40   0.4533
   Relative decrease ≥10%               0.90                                                0.59 to 1.38   0.6262
   Absolute decrease ≥5%                0.97                                                0.68 to 1.40   0.8805
   Relative decrease ≥5%                0.91                                                0.66 to 1.25   0.5548
  Death or absolute FVC decrease ≥10%   0.71                                                0.48 to 1.07   0.1032
  Death or 6MWD decrease ≥50 m          0.69                                                0.48 to 0.99   0.0465
  Hospitalisation                                                                                          
   All-cause                            0.58                                                0.35 to 0.94   0.0289
   Respiratory-related‡                 0.44                                                0.25 to 0.80   0.0063

\*Patients with missing baseline data were excluded from relevant analyses.

†Defined as ≥10% decrease in per cent predicted FVC, ≥50 m decline in 6MWD or death.

‡Hospitalisation in which the primary reason for admission was determined to be respiratory-related by a blinded clinical investigator.

6MWD, 6-minute walk distance; IPF, idiopathic pulmonary fibrosis.

Discussion {#s4}
==========

The results of this post hoc analysis of data from patients with IPF from the placebo arms of the CAPACITY and ASCEND trials provide support for the hypothesis that statin therapy may have a beneficial effect on IPF-related outcomes. In particular, statins were associated with reduced hospitalisation and mortality.

Previous studies undertaken to evaluate the potential impact of statins on outcomes in patients with IPF have provided conflicting results. A small, retrospective analysis of data from 35 patients with IPF did not show an association between statin therapy and mortality.[@R21] However, more than half of the patients in this study received immunosuppressive therapy which has recently been associated with increased mortality in the PANTHER trial[@R25] and which may, therefore, have confounded the results. In contrast, a more recent analysis of data from the national Danish Patients Registry found that statin use was associated with reduced mortality among 783 patients with IPF. However, the International Classification of Diseases, 10th revision coding was used in this analysis, and may have introduced bias due to poor definition of baseline lung function and other potential risk factors for adverse outcomes.[@R22]

Our analyses did not identify a beneficial interaction between statin use and current/former smoking status for any outcome contrary to previous observations reported by Alexeeff *et al*. Alexeeff *et al*[@R15] reported a statistically significant (p\<0.001) three-way interaction between time since first study visit, statin use and smoking status in elderly men enrolled in a longitudinal observational study. Their results suggested that statins might act by attenuating the negative effects of smoking on the normative decline in lung function associated with ageing. However, lung function decline in patients with IPF differs to that associated with normal ageing,[@R8] [@R26] [@R27] thus complicating valid comparison between the two populations.

The pathophysiology of IPF is very complex and the mechanism by which statins may affect cellular and/or molecular pathways to reduce disease progression remains to be explained. Repetitive microscopic injury to alveolar epithelial cells type II (AECII) is thought to be an important component of the pathogenesis of IPF. AECII death and perturbation of normal epithelial homoeostasis may result in uncontrolled repair mechanisms, resulting in fibroblast proliferation and activation and, ultimately, lung fibrosis.[@R28] [@R29] Multiple pathways are involved both in AECII death and in lung fibrosis, and the relative contribution of these pathways in the development of IPF is currently an important knowledge gap. In vitro studies have long suggested a modulatory effect of statins on pathways of fibrosis in humans.[@R30] [@R31] In experiments using a human renal fibroblast cell line (TK173), exposure to statins resulted in a reversible and time-dependent change in cell morphology, including the actin skeleton, with concomitant changes in the basal expression of the profibrotic protein connective tissue growth factor.[@R30] This finding was reproduced in an in vitro study that found a reduction in the expression of the profibrotic connective tissue growth factor in lung fibroblasts treated with statins.[@R32] Perhaps more indirectly, statins have been shown to reduce the expression of the glycoprotein thrombospondin-1 by human vascular smooth muscle cells;[@R31] thrombospondin-1 is a known activator of transforming growth factor-β (TGF-β), a key profibrotic protein implicated in fibrogenesis.[@R33]

Pathophysiological processes other than those related directly to fibrosis may also underpin a beneficial effect of statins in patients with IPF. Statins are known to exert an anti-inflammatory effect and it is possible that this action may explain the apparent protective effect of these agents in patients with IPF. In a rat model, statins appeared to be protective against smoking-induced lung damage through anti-inflammatory effects in the lung itself, particularly inhibition of inflammatory cell infiltration.[@R34] Consistent with this latter observation, statin use was associated with reduced levels of neutrophils and lymphocytes in the bronchoalveolar lavage fluid of patients after lung transplantation with a variety of underlying diagnoses including emphysema, cystic fibrosis and IPF. The 6-year survival of patients with lung transplant who received statins was also significantly greater than that of patients who did not receive statins (91% vs 54%; p\<0.01).[@R35] Furthermore, statins have been shown to suppress the production of TGF-β and the inflammatory chemokine, interleukin (IL) 8, in human lung tissue.[@R36] However, this is in contrast to an in vitro study which found that statins increased mitogen-activated peripheral blood monocyte secretion of IL-18 and IL-1β,[@R39] two cytokines that have been implicated in bleomycin-induced lung injury.[@R40]

Our analysis was the first evaluation of statin use in a large, well defined cohort of patients with IPF with regular follow-up. In contrast to earlier evidence which had suggested a link between statin use and the development of interstitial lung abnormalities[@R17] [@R18] our results add weight to the hypothesis that statins may exert a beneficial effect in patients with IPF. However, the conclusions that can be drawn are limited by the post hoc nature of the analysis. Statin therapy may address an increased risk of all-cause death or hospitalisation as a result of comorbid conditions. Yet a comparison of the baseline characteristics of the patients in the two groups suggested that those receiving statins had higher CV risk than those not receiving statins, as might be expected given the CV-related indications for statin therapy. Additionally, our analyses have suggested a potentially more specific effect of statins on IPF-related mortality and respiratory-related hospitalisations, which might not be anticipated if the impact of statins was related only to CV comorbidities.

Furthermore, our results are limited to patients with IPF who are not treated with antifibrotics. Future studies of statins in IPF are likely to include patients receiving antifibrotics, therefore a post hoc analysis designed to investigate the effect of pirfenidone and statins in combination is planned, using data from the pirfenidone arms of the ASCEND and CAPACITY studies.

Conclusions {#s5}
===========

In conclusion, the results presented here provide support for the hypothesis that statins may be beneficial in patients with IPF. Future studies should include prospective analyses of statin use in IPF and their potential use in combination with antifibrotic therapies.
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